FDA approves use of drug to reduce risk of cardiovascular events in certain adult patient groups
For Immediate Release: December 13, 2019 The U.S. Food and Drug Administration today approved the use of Vascepa (icosapent ethyl) as an adjunctive (secondary) therapy to reduce the risk of cardiovascular events among adults with elevated triglyceride …